|
|
???tair.name??? >
???browser.page.title.author???
|
"yamaguchi k"???jsp.browse.items-by-author.description???
Showing items 1-10 of 18 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
| 國家衛生研究院 |
2024-08-20 |
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 randomized, double-blind, placebo-controlled, phase 3 tri
|
Boku, N;Omori, T;Shitara, K;Sakuramoto, S;Yamaguchi, K;Kato, K;Kadowaki, S;Tsuji, K;Ryu, MH;Oh, DY;Oh, SC;Rha, SY;Lee, KW;Chung, IJ;Sym, SJ;Chen, LT;Chen, JS;Bai, LY;Nakada, T;Hagihara, S;Makino, R;Nishiyama, E;Kang, YK |
| 國家衛生研究院 |
2022-02 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): A randomised, multicentre, double-blind, placebo-contr
|
Kang, YK;Chen, LT;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Oh, SY;Choda, Y;Yasui, H;Takeuchi, K;Hirashima, Y;Hagihara, S;Boku, N |
| 國立成功大學 |
2022 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-contr
|
Kang, Y.-K.;Chen, L.-T.;Ryu, M.-H.;Oh, D.-Y.;Oh, S.C.;Chung, H.C.;Lee, K.-W.;Omori, T.;Shitara, K.;Sakuramoto, Sakuramoto S.;Chung, I.-J.;Yamaguchi, K.;Kato, Kato K.;Sym, Sym S.J.;Kadowaki, S.;Tsuji, K.;Chen, J.-S.;Bai, L.-Y.;Oh, S.-Y.;Choda, Y.;Yasui, H.;Takeuchi, K.;Hirashima, Y.;Hagihara, S.;Boku, N. |
| 臺大學術典藏 |
2021-02-04T06:04:28Z |
Optimal timing of influenza vaccine during pregnancy: A systematic review and meta-analysis
|
Cuningham W.;Geard N.;Fielding J.E.;Braat S.;Madhi S.A.;Nunes M.C.;Christian L.M.;Lin S.-Y.;Chien-Nan Lee;Yamaguchi K.;Bisgaard H.;Chawes B.;Chao A.-S.;Blanchard-Rohner G.;Schlaudecker E.P.;Fisher B.M.;Mcvernon J.;Moss R.; Cuningham W.; Geard N.; Fielding J.E.; Braat S.; Madhi S.A.; Nunes M.C.; Christian L.M.; Lin S.-Y.; CHIEN-NAN LEE; Yamaguchi K.; Bisgaard H.; Chawes B.; Chao A.-S.; Blanchard-Rohner G.; Schlaudecker E.P.; Fisher B.M.; McVernon J.; Moss R. |
| 國家衛生研究院 |
2020-09 |
Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
|
Boku, N;Ryu, MH;Oh, DY;Oh, SC;Chung, HC;Lee, KW;Omori, T;Shitara, K;Sakuramoto, S;Chung, IJ;Yamaguchi, K;Kato, K;Sym, SJ;Kadowaki, S;Tsuji, K;Chen, JS;Bai, LY;Chen, LT;Kang, YK |
| 臺大學術典藏 |
2020-03-27T05:31:03Z |
Multicentre evaluation of the in vitro activity of linezolid in the Western Pacific
|
PO-REN HSUEH; Liu Y.C.; Leu H.S.; Kumarasinghe G.; Yeo M.; Lee K.W.; Choi K.W.; Woo J.H.; Kahu M.; Kohno S.; Yamaguchi K.; Cheng A.; Tsang D.; Christiansen K.; Faoagali J.; Grayson L.; Benn R.; Turnidge J.; Ballow C.H.; Jones R.N.; Turnidge J.D.; Bell J.M.; Leu H.S.;Liu Y.C.;PO-REN HSUEH;Kumarasinghe G.;Yeo M.;Lee K.W.;Choi K.W.;Woo J.H.;Kahu M.;Yamaguchi K.;Kohno S.;Tsang D.;Cheng A.;Christiansen K.;Faoagali J.;Grayson L.;Benn R.;Turnidge J.;Jones R.N.;Ballow C.H.;Turnidge J.D.;Bell J.M. |
| 臺大學術典藏 |
2020-02-12T04:05:37Z |
Optimal timing of influenza vaccine during pregnancy: A systematic review and meta-analysis
|
Moss R.;McVernon J;Fisher B.M;Schlaudecker E.P;Blanchard-Rohner G;Chao A.-S;Chawes B;Bisgaard H;Yamaguchi K;CHIEN-NAN LEE;Lin S.-Y;Christian L.M;Nunes M.C;Madhi S.A;Braat S;Fielding J.E;Geard N;Cuningham W; Cuningham W; Geard N; Fielding J.E; Braat S; Madhi S.A; Nunes M.C; Christian L.M; Lin S.-Y; CHIEN-NAN LEE; Yamaguchi K; Bisgaard H; Chawes B; Chao A.-S; Blanchard-Rohner G; Schlaudecker E.P; Fisher B.M; McVernon J; Moss R. |
| 臺大學術典藏 |
2020-02-10T06:49:06Z |
Optimal timing of influenza vaccine during pregnancy: A systematic review and meta-analysis
|
Cuningham W;Geard N;Fielding J.E;Braat S;Madhi S.A;Nunes M.C;Christian L.M;Shin-Yu Lin;Lee C.-N;Yamaguchi K;Bisgaard H;Chawes B;Chao A.-S;Blanchard-Rohner G;Schlaudecker E.P;Fisher B.M;Mcvernon J;Moss R.; Cuningham W; Geard N; Fielding J.E; Braat S; Madhi S.A; Nunes M.C; Christian L.M; SHIN-YU LIN; Lee C.-N; Yamaguchi K; Bisgaard H; Chawes B; Chao A.-S; Blanchard-Rohner G; Schlaudecker E.P; Fisher B.M; McVernon J; Moss R. |
| 國立成功大學 |
2019 |
Safety and efficacy of nivolumab in combination with s-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: Interim results of a randomized, phase II trial (a
|
Boku, N.;Ryu, M.-H.;Kato, Kato K.;Chung, H.C.;Minashi, K.;Lee, K.-W.;Cho, H.;Kang, W.K.;Komatsu, Y.;Tsuda, M.;Yamaguchi, K.;Hara, Hara H.;Fumita, S.;Azuma, M.;Chen, L.-T.;Kang, Y.-K. |
| 國立成功大學 |
2019 |
A subanalysis of Japanese patients in a randomized, double-blind, placebo-controlled, phase 3 trial of nivolumab for patients with advanced gastric or gastro-esophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy re
|
Kato, Kato K.;Satoh, T.;Muro, K.;Yoshikawa, T.;Tamura, Tamura T.;Hamamoto, Y.;Chin, K.;Minashi, K.;Tsuda, M.;Yamaguchi, K.;Machida, N.;Esaki, T.;Goto, M.;Komatsu, Y.;Nakajima, T.E.;Sugimoto, N.;Yoshida, K.;Oki, E.;Nishina, T.;Tsuji, A.;Fujii, H.;Kunieda, Kunieda K.;Saitoh, Saitoh S.;Omuro, Y.;Azuma, M.;Iwamoto, Y.;Taku, K.;Fushida, S.;Chen, L.-T.;Kang, Y.-K.;Boku, N. |
Showing items 1-10 of 18 (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page
|
